Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
IMRX Stock Chart & Stats
$6.14
-$0.24(-10.17%)
At close: 4:00 PM EST
$6.14
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.10 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)2.77M
Market Cap
$371.05M
Enterprise Value$98.92M
Total Cash (Recent Filing)$26.36M
Total Debt (Recent Filing)$4.00M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Nov 06, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding60,530,140
10 Day Avg. Volume2,531,857
30 Day Avg. Volume2,769,109
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue136.19
Enterprise Value/Gross Profit-1.24K
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$15.20Price Target Upside147.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsThe announcement of a new clinical supply agreement with Lilly for evaluating a combination therapy in certain NSCLC patients significantly boosted the stock.
Stock PotentialThere is significant upside potential in the stock at current levels, ahead of its data for the Ph 2a study of atebimetinib + GnP in 1L PDAC.
Strategic PartnershipsA second clinical supply agreement this year with Regeneron for Libtayo further strengthens the company's strategic partnerships.
Bears Say
Earnings PerformanceThe company reported an earnings per share of -$0.40, which is mostly in line with the consensus of -$0.42.
Safety ConcernsThe safety profile deteriorated slightly with higher percentages of neutropenia, anemia, and fatigue.
Immuneering News
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.10 and its highest was $10.08 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $371.05M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Nov 06, 2025 which is in 22 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Aug 13, 2025. The company reported -$0.4 earnings per share for the quarter, the consensus estimate of -$0.4 by $0.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.41.
How many shares outstanding does Immuneering have?
Immuneering has 60,530,140 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.4 in its last earnings report, expectations of -$0.4. Following the earnings report the stock price went down -5.59%.
Which hedge fund is a major shareholder of Immuneering?
Among the largest hedge funds holding Immuneering’s share is Perceptive Advisors LLC. It holds Immuneering’s shares valued at 0.
Immuneering Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.20 (147.56% Upside)
$15.20 (147.56% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $152.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.8%
Last 30 Days ▲ 36.8%
Last 30 Days ▲ 36.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
180.36%
12-Months-Change
Fundamentals
Return on Equity
-130.47%
Trailing 12-Months
Asset Growth
-48.04%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$15.20
▲(147.56% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
I-MAB
―
Invivyd
―
Aura Biosciences Inc
―
Ownership Overview
14.46% Insiders
3.39% Mutual Funds
1.17% Other Institutional Investors
78.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---